Normal view MARC view ISBD view

A wheel-chair. [electronic resource]

By:

POOLE, A G B

Producer: 20080121Description: 480-2 p. digitalISSN:

0140-6736

Subject(s):

In: Lancet (London, England) vol. 1

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

3221 Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
by Zanotto-Filho, Alfeu
3222 RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
by Yeom, Seon-Yong
3223 Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
by Suchorska, Bogdana
3224 Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
by Wong, Eric T
3225 Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
by Ammirati, Mario
3226 Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
by Pietrantonio, F
3227 Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
by Cong, Zi-Xiang
3228 Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
by Wang, Xiao-xiao
3229 RIST: a potent new combination therapy for glioblastoma.
by Nonnenmacher, Lisa
3230 Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
by Ishikawa, Eiichi
3231 mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
by Smalley, Sarah
3232 c-Myc modulation: a key role in melanoma drug response.
by Fico, Annalisa
3233 Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
by Bell, Erica Hlavin
3234 Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
by Lan, Tian
3235 Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.
by Braun, Christian J
3236 Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
by He, Jin-Xue
3237 A Potential Nanofiber Membrane Device for Filling Surgical Residual Cavity to Prevent Glioma Recurrence and Improve Local Neural Tissue Reconstruction.
by Huang, Daoxiang
3238 Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
by Gill, Sonja J
3239 Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
by Xipell, Enric
3240 PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
by Engert, Florian